trending Market Intelligence /marketintelligence/en/news-insights/trending/m1zmf_l0N9DjZj3Awv6NCw2 content esgSubNav
In This List

Eli Lilly cancer drug meets endpoint in phase 3 trial

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Eli Lilly cancer drug meets endpoint in phase 3 trial

Eli Lilly & Co.'s Cyramza met its primary endpoint in a phase 3 trial involving patients with a certain kind of bladder cancer.

The drug, in combination with docetaxel, showed that urothelial carcinoma patients whose disease progressed on or after platinum-based chemotherapy achieved superior progression-free survival when compared to chemotherapy.

Although the primary endpoint has been met, Lilly anticipates that overall survival results are likely to be required for global regulatory submissions.

Final overall survival results are expected in mid-2018.

Cyramza is already approved for certain types of cancer, including metastatic non-small cell lung cancer in combination with docetaxel.